Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Quinol-fumarate reductase (QFR) in Escherichia coli is a four-subunit integral membrane enzyme complex responsible for catalyzing the final step of anaerobic respiration by reducing fumarate to succinate, using reduced quinones (primarily menaquinol) as electron donors. It is functionally distinct from the homologous succinate dehydrogenase (aerobic, Complex II), with QFR preferentially operating under anaerobic conditions to enable E. coli growth when fumarate is the terminal electron acceptor. QFR's structure includes flavoprotein, iron-sulfur protein, and membrane-spanning subunits with multiple redox-active cofactors, facilitating electron transfer from the membrane-bound quinol through iron-sulfur clusters to FAD, and finally to fumarate. Inhibitors that block the quinol-binding site (e.g., HQNO) have been structurally characterized, demonstrating druggability of this bacterial respiratory target. QFR is essential for E. coli's energy metabolism in low-oxygen environments and provides a model for respiratory adaptation in anaerobes.
Competitive inhibition of quinol binding site, blocking electron transfer and fumarate reduction
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Quinol-fumarate reductase (QFR).